| Vol. 13.13 – 25 April, 2022 |
| |
|
|
| Investigators started with a CD27-based CAR to target CD70 in acute myeloid leukemia, and they found modest efficacy in vivo, consistent with prior reports. [Cancer Cell] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| To overcome the challenges faced with CAR-T cells using donor-derived conventional CD4+ or CD8+ T cells, scientists evaluated the feasibility, safety, and efficacy of using healthy donor–derived allogeneic double-negative T cells as a CAR-T cell therapy platform. [Science Immunology] |
|
|
|
| Researchers established a lung and macrophage co-culture system derived from human pluripotent stem cells, modeling the host-pathogen interaction in SARS-CoV-2 infection. [Nature Communications] |
|
|
|
| Scientists studied the direct impact of granulocyte-macrophage colony-stimulating factor (GM-CSF) disruption during the production of CD19-directed CART cells on their effector functions, independent of GM-CSF modulation of myeloid cells. [Leukemia] |
|
|
|
| To improve the efficacy and safety of glypican-3 (GPC3)-targeted adoptive cell therapies, T cells were modified with anti-GPC3 single-chain fragment variable (sFv) linked to CD3ε, which could be incorporated into the entire TCR/CD3 complex to form chimeric sFv-CD3ε receptor (sFv-ε). [Molecular Therapy Oncolytics] |
|
|
|
| The authors generated CARCys-T cells using a 4-1BB-derived hinge region including 11 cysteines residues. The cysteines in the hinge were found to facilitate CARCys clustering upon antigen stimulation and promote the antitumor activity of CAR-T cells. [Cancer Immunology Immunotherapy] |
|
|
|
| Investigators attempted to determine whether L-DOPA impacted the survival and functional recovery following grafting of human embryonic stem cell-derived dopaminergic neurons. [Journal of Parkinsons Disease] |
|
|
|
| The authors examined whether bladder detrusor dysfunction due to partial bladder outlet obstruction could be improved after the treatment of human amniotic fluid stem cells. [Scientific Reports] |
|
|
|
| Researchers established some important characteristics that can be used to distinguish between MSC-NTF and MSCs: different multi-factor secretion ability and secretion characteristics, immunogenicity, three-line differentiation ability, stemness, etc. [Experimental Cell Research] |
|
|
|
|
| It is crucial to discover and develop reliable and robust biomarkers to specifically and sensitively pinpoint the patients that will benefit the most from adoptive cell therapy, as well as those that are at higher risk of developing potentially serious toxicities. [JNCI-Journal of the National Cancer institute] |
|
|
|
| Thus far, therapy with mesenchymal stem cells appears to be safe for use in humans, as no severe adverse events directly related to the therapy were reported. [Epilepsia] |
|
|
|
|
| Suzhou Porton Advanced Solutions Ltd. and Guizhou Sinorda Biomedicine Co. Ltd announced a long-term strategic partnership in cell and gene therapy R&D and platform development. [Suzhou Porton Advanced Solutions Ltd. (Businesswire, Inc.)] |
|
|
|
| Mustang Bio, Inc. announced updated interim data from the ongoing Phase I/II clinical trial of MB-106, a CD20-targeted, autologous CAR T cell therapy for patients with relapsed or refractory B cell non-Hodgkin lymphomas and chronic lymphocytic leukemia [Mustang Bio] |
|
|
|
|
| June 26 – 28, 2022 Basel, Switzerland |
|
|
|
|
|
|
| St. Jude Children’s Research Hospital – Memphis, Tennessee, United States |
|
|
|
| Novo Nordisk – Fremont, California, United States |
|
|
|
| Stanford University – Stanford, California, United States |
|
|
|
| Fred Hutchinson Cancer Research Center – Seattle, Washington, United States |
|
|
|
|